Drug name - Fosrenol
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 10 months from now) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 10 months from now) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(8 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(8 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1GM BASE | POWDER;ORAL | Prescription |
| EQ 750MG BASE | POWDER;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.